Recent Updates
Recently added Catalysts
ALLR Negative Sentiment Score: 25/100

Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Key Takeaway: Allarity Therapeutics, Inc. is currently under investigation by Bronstein, Gewirtz & Grossman, LLC for potential claims following a Wells Notice issued by the SEC. The Wells Notice pertains to the company's disclosures related to its New Drug Application for Dovitinib, suggesting possible violations of federal securities laws. Additionally, three former officers received similar notices, indicating significant regulatory scrutiny. This situation has led to a decline in Allarity's stock price.

Market Sentiment Analysis

CONCERNS & RISKS

  • Allarity Therapeutics received a Wells Notice from the SEC indicating potential violations of federal securities laws.
  • The investigation relates to disclosures concerning the company's NDA for Dovitinib, which raises concerns about regulatory compliance.
  • Three former officers of Allarity also received Wells Notices related to the same conduct, indicating broader issues within the company.
  • Following the announcement, Allarity's stock price experienced a decline.

Full Press Release Details

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. (“Allarity” or “the Company”) (NASDAQ: ALLR). Investors who purchased Allarity securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ALLR.
Investigation Details
On July 22, 2024, Allarity filed a current report on Form 8-K with the SEC and disclosed that, “Allarity Therapeutics, Inc. (the ‘Company’) received a ‘Wells Notice’ from the Staff of the U.S. Securities and Exchange Commission (the ‘SEC’) relating to the Company’s previously disclosed SEC investigation.” Allarity also revealed that “[t]he Wells Notice relates to the Company’s disclosures regarding meetings with the United States Food and Drug Administration (the ‘FDA’) regarding the Company’s NDA [New Drug Application] for Dovitinib or Dovitinib-DRP,” and that “Allarity also understands that three of its former officers received Wells Notices from the SEC relating to the same conduct.” Further, “[t]he Wells Notice informed the Company that the SEC Staff has made a preliminary determination to recommend that the SEC file an enforcement action against the Company that would allege certain violations of the federal securities laws.” Following this news, Allarity stock price dropped.
If you are aware of any facts relating to this investigation or purchased Allarity securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ALLR. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What investigation is Bronstein, Gewirtz & Grossman conducting?

They are investigating potential claims for purchasers of Allarity Therapeutics.

What was disclosed in Allarity's July 22 report?

Allarity disclosed receiving a 'Wells Notice' from the SEC regarding its investigation.

What does the Wells Notice relate to?

It concerns Allarity's disclosures about FDA meetings regarding its NDA for Dovitinib.

How does Bronstein, Gewirtz & Grossman charge for their services?

They operate on a contingency fee basis, charging only if they are successful.

How can I assist with the investigation?

You can assist by visiting bgandg.com/ALLR or contacting the firm directly.

Last updated: Aug 1, 2024